Arbutus Biopharma is a virology-focused biotech company dedicated to providing clinical and pre-clinical assets to patients in need. As a healing plant native to North America, Arbutus draws inspiration from its namesake, leveraging its growing portfolio of innovative assets to address unmet medical needs. Their virology pipeline encompasses active clinical and pre-clinical studies in the areas of Hepatitis B virus (HBV) and pan-coronavirus.

Arbutus sets itself apart with a broad and innovative virology portfolio, focusing on combination regimens for maximum impact and drawing on deep experience in drug development. For HBV, they employ a unique Suppress, Reduce, Boost method using complementary agents to pursue a cure. In the case of coronavirus, their expertise allows them to develop direct-acting antivirals targeting key enzymes to treat COVID-19 and other coronaviruses.

Through their dedication and expertise, Arbutus Biopharma strives to heal a world in need